AXA-NK02
Phase 1Biologic
AXA-NK02 is one of 40 biologic programs targeting Lupus Nephritis. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Lupus Nephritis
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Medrol
PfizerApproved
Rituxan
RocheApproved
Cytoxan
BBaxter Healthcare Corporation
Approved
Farxiga
AstraZenecaApproved
Myfortic
NovartisApproved
Rocaltrol
Jazz PharmaceuticalsApproved
Imuran
LLegacy Health System
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Neoral
NovartisApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AXA-NK02. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details